Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature review

被引：0
作者：
Ke Cheng
Xia Liu
Ye Chen
Kexun Zhou
ZhiPing Li
机构：
[1] Sichuan University,Department of Abdominal Oncology, Cancer Center of West China Hospital
来源：
BMC Gastroenterology | / 22卷
关键词：
Intra-abdominal desmoplastic small round cell tumor; Chemotherapy; Anlotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 34 条
[31]   A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review [J].
Liu, Ying ;
Li, Mingyang ;
Guo, Yu ;
Zhang, Zhiyong ;
Du, Liuyang ;
Zhang, Xiaotong ;
Wang, Yingping ;
Zhang, Dong ;
Xue, Lingfei ;
Lei, Binhua ;
Su, Jing ;
Zhang, Ruiwen ;
Chen, Jiaohong ;
Zhang, Xiangqian ;
Jia, Qingge ;
Tian, Chuntao .
PATHOLOGY RESEARCH AND PRACTICE, 2024, 259
[32]   Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review [J].
Wang, Yunpeng ;
Wang, Bofang ;
Xiang, Lin ;
Deng, Junge ;
Xu, Bo ;
He, Puyi ;
Pu, Weigao ;
Wang, Haiyun ;
Fan, Yong ;
Chen, Hao .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[33]   Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review [J].
Liu, Zhichao ;
Bao, Youting ;
Li, Butuo ;
Sun, Xindong ;
Wang, Linlin .
CLINICAL AND TRANSLATIONAL MEDICINE, 2018, 7
[34]   Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/ PD-L1 antibodies in extensive-stage small cell lung cancer: a real world study [J].
Yang, Pan ;
Luo, Hu ;
Zhao, Lintao ;
Xiong, Fu ;
Tang, Chunlan .
JOURNAL OF THORACIC DISEASE, 2024, 16 (07) :4391-4399
1234